Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alzamend NeuroALZN -0.59%21 3-Year EBITDA Growth Rate is 77.50% as of Apr. 2026. GuruFocus rates ALZN with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 1,127 Biotechnology companies, Alzamend Neuro ranks better than 95.83% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 77.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 52.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Alzamend Neuro was 77.50% per year. The lowest was -50.60% per year. And the median was -19.30% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Alzamend Neuro 3-Year EBITDA Growth Rate Related Terms
ALZN vs CNSP, SNGX, AIM: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Alzamend Neuro's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alzamend Neuro 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alzamend Neuro's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Alzamend Neuro's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 77.50% mean?
Alzamend Neuro (ALZN) has a 3-Year EBITDA Growth Rate of 77.50% as of Apr. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Alzamend Neuro and its competitors. According to the industry distribution chart, Alzamend Neuro ranks #47 out of 1127 companies in the Biotechnology industry, placing it in the top 4.2%.
Is Alzamend Neuro's 3-Year EBITDA Growth Rate too high?
Alzamend Neuro's current 3-Year EBITDA Growth Rate is 77.50%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.70. Alzamend Neuro's value of 77.50% is 427.2% above this industry median. Based on the distribution chart, Alzamend Neuro ranks #47 out of 1127 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alzamend Neuro has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Alzamend Neuro's 3-Year EBITDA Growth Rate compare to CNSP and SNGX?
According to the Biotechnology industry distribution chart, Alzamend Neuro ranks #47 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Alzamend Neuro in the top 4% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.70. Alzamend Neuro's value of 77.50% is 427.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.70, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alzamend Neuro's current 3-Year EBITDA Growth Rate of 77.50% is 427.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Alzamend Neuro and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alzamend Neuro's current 3-Year EBITDA Growth Rate is 77.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alzamend Neuro stock overvalued right now?
Alzamend Neuro (ALZN) has a current 3-Year EBITDA Growth Rate of 77.50%. The current 3-Year EBITDA Growth Rate is 77.50% and 427.2% above the Biotechnology industry median of 14.70. Alzamend Neuro's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Alzamend Neuro (ALZN), the current 3-Year EBITDA Growth Rate is 77.50% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
21GF Score
Get the complete analysis for ALZN
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALZN has been successfully added to your 
